- Home
- BIOA
as 02-21-2025 4:00pm EST
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
Upcoming Earnings Alert:
Get ready for potential market movements as BioAge Labs Inc. Common Stock BIOA prepares to release earnings report on 28 Feb 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 162.0M | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 233.5K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -33.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $26.62 | Next Earning Date: | 02-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioAge Labs Inc. Common Stock News
BIOA Breaking Stock News: Dive into BIOA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
BioPharma Dive
24 days ago
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
MT Newswires
25 days ago
BioAge Labs Terminates Azelapra Development
GlobeNewswire
25 days ago
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
Pharma Voice
a month ago
After an obesity stumble, BioAge reconnects with its longevity pipeline
Zacks
2 months ago
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insider Monkey
2 months ago
BioAge Labs, Inc. (BIOA): A Bull Case Theory
Pharmaceutical Technology
2 months ago
BioAge and Novartis seek drug targets for ageing-related diseases
Compare BIOA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIOA BioAge Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.